Respiratory medications and the risk of cardiac arrhythmias

Epidemiology

Volumn 16, Issue 3, 2005, Pages 360-366

  Huerta, Consuelo ^a   Lanes, Stephan F ^b   García Rodríguez, Luis A ^a  

^a Department of Pharmacoepidemiology   (Spain)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CISAPRIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; RESPIRATORY TRACT AGENT; THEOPHYLLINE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; EVALUATION; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART DEATH; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; LOGISTIC REGRESSION ANALYSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; SHORT COURSE THERAPY; SINUS ARRHYTHMIA; SUPRAVENTRICULAR PREMATURE BEAT; SUPRAVENTRICULAR TACHYCARDIA; UNITED KINGDOM;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; ARRHYTHMIA; ASTHMA; BRONCHODILATOR AGENTS; CASE-CONTROL STUDIES; CHILD; FEMALE; GREAT BRITAIN; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 17844399598     PISSN: 10443983     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ede.0000158743.90664.a7     Document Type: Article

References (23)

1. Current Estimates from the National Health Interview Survey, 1993. Vital Health Statistics, US Department of Health and Human Services, Public Health Services, December 1994;83.
2. De Ponti F, Poluzzi E, Montanaro N. Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus. Eur J Clin Pharmacol. 2001;57:185-209.
3. Doig JC. Drug-induced cardiac arrhythmias: incidence, prevention and management. Drug Saf. 1997;17:256-275.
4. Bouvy ML, Heerdink ER, De bruin ML, et al. Use of sympathomimetic drugs leads to increased risk of hospitalization for arrhythmias in patients with congestive heart failure. Arch Intern Med. 2000; 160:2477-2480.
5. Haffner CA, Kendall MJ. Metabolic effects of beta 2-agonists. J Clin Pharmacol Ther. 1992;17:155-164.
6. Yang T, Roden D. Extracellular potassium modulation of drug block of I sub Kr: implications for torsades de pointes and reverse use-dependence. Circulation. 1996;93:407-411.
7. Bittar G, Friedman HS. The arrhythmogenicity of theophylline. A multivariate analysis of clinical determinants. Chest. 1991;99:1415-1420.
8. Anthonisen NR, Connett JE, Enright PL, et al. Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med. 2002;166:333-339.
9. Cazzola M, Imperatore F, Salzillo A, et al. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest. 1998;114:411-415.
10. Bennet JA, Tattersfield AE. Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects. Thorax. 1997;52:458-464.
11. García Rodríguez LA, Pérez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol. 1998;45:419-426.
12. García Rodríguez LA, Pérez Gutthann S, Jick S. The UK General Practice Research Database. In: Strom BL, ed. Pharmacoepidemiology, 3rd ed. Chichester: Wiley; 2000:375-385.
13. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ. 1991;302:766-768.
14. De Abajo FJ, García Rodríguez LA. Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs. J Clin Pharmacol. 1999;47:307-313.
15. Walker AM, Szneke P, Weatherby LB, et al. The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada. Am J Med. 1999;107:356-362.
16. Krahn AD, Manfreda J, Tate RB, et al. Incidence, risk factors and prognosis in the Manitoba Follow-Up Study. Am J Med. 1995;98:476-484.
17. Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997;96:2455-2461.
18. Osman F, Gammage MD, Franklyn JA. Hyperthyroidism and cardiovascular morbidity and mortality. Thyroid. 2002;12:483-487.
19. Auer J, Scheibner P, Mische T, et al. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am Heart J. 2001;142:838-842.
20. Suissa S, Hemmelgarn B, Blais L, et al. Bronchodilators and acute cardiac death. Am J Respir Crit Care Med. 1996;154:1598-1602.
21. Suissa S, Assimes T, Ernst P. Inhaled short acting beta agonist use in COPD and the risk of acute myocardial infarction. Thorax. 2003;58:43-46.
22. Au DH, Lemaitre RN, Curtis JR, et al. The risk of myocardial infarction associated with inhaled b-adrenoceptor agonist. Am J Respir Crit Care Med. 2000;161:827-830.
23. Au DH, Curtis RJ, Every NR, et al. Association between inhaled [beta]-agonists and the risk of unstable angina and myocardial infarction. Chest. 2002;121:846-851.